Premium
P3–237: Office‐based assessment of driving safety in older drivers with and without dementia
Author(s) -
Abularach Linda,
Seichepine Daniel,
Tripodis Yorghos,
Gavett Brandon,
Stern Robert
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1310
Subject(s) - driving test , test (biology) , dementia , cognitive test , cognition , pace , psychology , medicine , physical medicine and rehabilitation , applied psychology , psychiatry , logistic regression , paleontology , disease , geodesy , pathology , biology , geography
low clinical utility. Yet, as early detection becomes more reliable, this justification will not hold and the challenges of early detection will have to be confronted directly. One feature of this landscape is the variation in circumstances that could substantially alter the impact of disclosure. It is essential that policy be devised to address vulnerabilities created by circumstances that could also lead to various forms of disparate impact. Methods: This work explores the nature of vulnerability that arises from variation in circumstance, identifying overlap with genetic testing vulnerability and other relevant disease indicator-status disclosures. Employing legal and policy analysis of relevant protective law and regulation, this work develops a point plan for policy development for disclosure of pre-clinical Alzheimer’s. Results: Development of policy and law regarding just integration of disclosure of pre-clinical Alzheimer’s should not rely entirely on existing legislative and regulatory approaches. Rather the nature of vulnerabilities exposed by pre-clinical AD diagnosis is such that it requires consideration of aspects not addressed sufficiently or in the same way as may be found in other types of disease indicator-status protection legislation (e.g. GINA).While there is substantial overlap in rights, less overlap may be found as regards duties and obligations, and hence the attendant rights.Conclusions: The implications of realization of reliable detection of pre-clinical Alzheimer’s disease should not be underestimated. Introduction of early detection technology into clinical practice requires consideration of implications for a diverse society. This work addresses the aspect of differential impact and vulnerability due to variation in circumstances, and offers suggestions for policy and legal approaches to accommodate variation in circumstances in disclosure of preclinical Alzheimer’s disease.